Navigation Links
Univfy and Stanford Scientists Develop the First Personalized Prognostic Test to Predict Live Birth Outcomes with In Vitro Fertilization
Date:7/19/2010

LOS ALTOS, Calif., July 19 /PRNewswire/ -- Univfy, a pioneer in the development of personalized in vitro fertilization (IVF) prognostic tools, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by its founding scientific team and clinical collaborators from Stanford University.  The peer-reviewed paper details their development of the first rigorously validated prognostic test for predicting IVF live birth outcomes for patients who have failed their first IVF attempt. In their validation test, this novel prognostic algorithm showed a more than 1000-fold improved live birth outcome prediction when compared to the age-based prediction model that is commonly used today (p<0.05).  Using this prediction model, the validation data showed that more than 60 percent of patients in the study received a significantly different, yet more accurate, prediction of live birth outcome in a subsequent IVF cycle as compared to conventional age-based prediction.

Stanford scientists, including Univfy's co-founders, developed the proprietary algorithm by examining 52 prognostic factors, such as body mass index, embryo development, and response to hormonal medications, along with analyzing the impact of those factors on IVF live birth success. The researchers extracted IVF outcomes data from more than 5000 IVF cycles performed at Stanford Hospital and Clinics from 2003-2008. 1676 treatments comprised the training data set that was used to generate the prediction model, which was subsequently validated in a separate set of 634 treatments that were performed in 2007-2008 in an unrelated group of patients.  

Univfy has obtained the exclusive license from Stanford University to develop and market this technology (patent pending), and plans to offer test services to patients and physicians in the fall of 2010, subject to clearance for use by the U.S. Food and Drug Administration (FDA).  These new prognostic tests would allow IVF physicians to provide live birth probabilities that are specific to each patient – and thus, are more meaningful – to best inform them as they navigate the difficult decisions that often come with IVF treatment.

"We believe that providing high quality, customized prognostics will empower patients with the information they need to make IVF decisions with greater confidence. We are excited about this merging of personalized medicine with reproductive medicine," stated Mylene W. M. Yao, M.D., president and co-founder of Univfy.  "Since this model uses clinical data from a previously failed IVF attempt, a first IVF treatment can be viewed both as an infertility treatment and as a potential prognostic tool for future cycles. Most remarkably, Univfy's proprietary algorithms do not require any additional blood tests or medical procedures, but rather, utilize a patient's existing clinical data to provide a personalized and highly accurate probability of live birth."

About IVF and the U.S. Infertility Market

Today, approximately 7.2 million couples in the U.S. and 60-80 million couples worldwide are affected by infertility.  First successfully utilized in the late 1970s, IVF is the process of fertilizing an egg with sperm outside of the womb and culturing the resulting embryos in vitro, until they are transferred back to the womb three to five days later.

Since its inception, IVF has been credited with the birth of more than one million babies worldwide.  The total number of IVF cycles attempted in the U.S. has increased by three to six percent each year, reaching approximately 140,000 IVF cycles in 2008, which represents a less than two percent utilization rate for IVF.  This low usage rate might be explained by barriers such as high treatment costs, minimal or lack of insurance coverage in many states, emotional stress, and the lack of patient-specific outcome prediction.

The market for infertility treatment in the U.S. alone is estimated at more than $3B. The most significant segment of the infertility market is in vitro fertilization (IVF), which accounts for over $2B.

About Univfy

Univfy was founded in November 2009 by Stanford University professors, Mylene Yao, M.D., and Wing Wong, Ph.D., who developed a novel approach to predicting live birth outcomes in in vitro fertilization (IVF).  The company is committed to helping infertile patients build healthy families by delivering personalized prognostic tests that support physicians and empower patients during infertility treatment decision-making.  

For more information about Univfy, please visit: www.univfy.com.

About the Stanford Research Team

The academic research that is the basis for Univfy's platform was led by Stanford scientists M. Yao, M.D., Wing H. Wong, Ph.D., Prajna Banerjee, Ph.D., and Bokyung Choi, Ph.D. candidate, and clinical collaborators Drs. L. Westphal, R. Lathi, L. Shahine (currently at Pacific Northwest Fertility and IVF Specialists), K. O'Leary, and S. Jun (currently at Palo Alto Medical Foundation). The academic work was funded by the NIH, NICHD, and the Stanford-Coulter Translational Research award.


'/>"/>
SOURCE Univfy
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stanford scientists develop new way to grow adult stem cells in culture
2. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
3. LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory
4. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
5. Stanford researchers find a quicker, cheaper way to sort isotopes
6. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
7. Stanford writes in worlds smallest letters
8. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
9. Cell Biosciences Delivers Next Generation System to Stanford University
10. Stanford: Quantum computing spins closer
11. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):